What drives a clinical trial investigator? The chance to support progress in science for patients. | Regeneron

🌟 Did you know? Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer, with an estimated 1.8 million cases diagnosed each year in the U.S. – and continues to be on the rise. People with CSCC with a high risk of recurrence have a greater chance of the cancer coming back after treatment, which is why identification of high-risk features is so important. Stay informed, prioritize skin health and consult a healthcare provider for regular check-ups. ✅ | Regeneron

🌟 Yesterday we announced our plans to acquire 23andMe and maintain its operations as a top consumer genetics company. We’re excited to strengthen our leadership in genetics-guided research and drug development for the betterment of patients, while prioritizing the privacy, security and ethical use of 23andMe’s customer data. We are committed to handling the data and services with the utmost care and aim to unlock 23andMe's full potential to benefit individual health and society as a whole. 💡💪

À seulement 18 ans, Matteo Paz remporte le prestigieux concours Regeneron Science Talent Search pour sa découverte de 1,5 million d’objets cachés dans l’univers. Abonne-toi pour ➕ d’initiatives positives ! 🍀 | Le Média Positif